NephroNet Clinical Research Consortium Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2018
NCT03502031
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

NephroNet, Inc. | NephroNet President